Gradient Investments LLC Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Gradient Investments LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 16,437 shares of the biopharmaceutical company’s stock, valued at approximately $1,287,000.

A number of other hedge funds have also recently made changes to their positions in HALO. Larson Financial Group LLC lifted its holdings in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the period. Measured Wealth Private Client Group LLC lifted its holdings in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the period. Harbour Investments Inc. boosted its position in Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 372 shares during the last quarter. Clearstead Advisors LLC boosted its position in Halozyme Therapeutics by 64.8% during the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 331 shares during the last quarter. Finally, Wexford Capital LP acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth about $70,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the sale, the director owned 42,044 shares of the company’s stock, valued at approximately $3,225,195.24. This trade represents a 3.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total value of $153,397.71. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $61,245,810.60. The trade was a 0.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 72,477 shares of company stock valued at $5,102,643. Company insiders own 2.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. UBS Group reissued a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. HC Wainwright upped their target price on Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a research report on Friday. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. TD Cowen boosted their price target on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Friday. Finally, Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and set a $110.00 price target on the stock in a report on Friday. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $91.20.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record Q2 results beat expectations: Halozyme reported adjusted earnings of $2.28 per share, above the roughly $1.79-$1.82 consensus, while revenue rose 48% year over year to $481 million versus estimates near $402 million. Royalty revenue increased 50% to $308 million. Halozyme reports record second quarter 2026 results
• Positive Sentiment: 2026 guidance was raised: Management now expects revenue of $1.835 billion-$1.910 billion, royalty revenue of $1.220 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS range is above the approximately $8.02 analyst consensus. Halozyme Q2 earnings beat estimates
• Positive Sentiment: Commercial momentum expanded: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s royalty-driven platform model and broaden future revenue opportunities.
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO to “outperform” with a $110 price target. HC Wainwright raised its target to $115 and retained a “buy” rating, while TD Cowen increased its target to $105 and also rated the stock “buy.”
• Neutral Sentiment: Analyst views remain mixed at the elevated valuation: Citizens JMP raised its target to $93 with a “market outperform” rating, and Wells Fargo lifted its target to $95 while maintaining “equal weight.” Both targets remain below the recent trading level, suggesting some analysts see limited near-term upside.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $103.12 on Monday. The firm has a market capitalization of $11.70 billion, a P/E ratio of 30.78, a P/E/G ratio of 0.43 and a beta of 0.85. The firm’s 50-day moving average price is $76.48 and its 200-day moving average price is $71.48. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $103.30.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same period last year, the business posted $1.54 EPS. The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.